Authors
Latest:
Dr. Drake on the Role of Cytoreductive Nephrectomy in RCCCharles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the role of cytoreductive nephrectomy in the treatment of patients with renal cell carcinoma.
Latest:
Dr. Mullighan on Germline Predisposition to ALLCharles G. Mullighan, MBBS, MSc, MD, member, St. Jude Faculty, deputy director, Comprehensive Cancer Center, co-leader, Hematological Malignancies Program, medical director, St. Jude Biorepository, William E. Evans Endowed Chair, St. Jude Children’s Research Hospital, discusses germline predisposition to acute lymphoblastic leukemia (ALL).
Latest:
Benefit of Maintenance Olaparib in Patients With Ovarian CancerCharlie Gourley, PhD, MBChB, chair and honorary consultant in Medical Oncology at Edinburgh Cancer Research Centre in the United Kingdom, discusses a study comparing the use of olaparib (Lynparza) after chemotherapy with placebo after chemotherapy in patients with platinum-sensitive ovarian cancer.
Latest:
Dr. Link on Algenpantucel-L for Pancreatic CancerCharles J. Link, Jr, MD, from the Cancer Center of Iowa and NewLink Genetics, discusses the phase II trial of algenpantucel-L for pancreatic cancer.
Latest:
Dr. Ryan on Bone-Targeting Agents for Patients With Prostate CancerCharles J. Ryan, MD, professor of medicine and urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses bone-targeting agents for patients with prostate cancer.
Latest:
Dr. Sawyers on the Negative Results of the IMbassador250 Trial in mCRPCCharles L. Sawyers, MD, discusses the negative results on the IMbassador250 trial in metastatic castration-resistant prostate cancer.
Latest:
Dr. Shapiro on Preventative Drugs in Breast CancerCharles L. Shapiro, MD, professor, College of Medicine, The James, Ohio State University Comprehensive Care Center, discusses the underutilization of preventative drugs for breast cancer.
Latest:
The Clinical and Economic Value of Rituximab for the Treatment of Hematologic MalignanciesRituximab is a humanized monoclonal antibody that is used for the treatment of a wide variety of B-cell-derived hematologic malignancies
Latest:
Charles Perou on Biomarker Assay Use in ASCO Breast Cancer GuidelineCharles M. Perou, PhD, May Goldman Shaw Distinguished Professor of Molecular Oncology, professor of Genetics, and Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, discusses the biomarker assay results as described in the ASCO breast cancer guideline.
Latest:
Clinical Practice Pearls and the Future of SCLCThe panel shares clinical pearls for community oncologists treating small cell lung cancer.
Latest:
Second Line Treatment Options in SCLC and Selecting the Appropriate TherapyThe panel discusses the second line treatment options in SCLC and how they choose among the various options based on patient and disease characteristics.
Latest:
Optimizing the Management of ILD: Take-Home MessagesExperts highlight key messages regarding optimal identification and management of interstitial lung disease.
Latest:
Dr. Fuchs Discusses Immunotherapy in Gastric CancerCharles S. Fuchs, MD, MPH, director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital, 2017 Giant of Cancer Care in Gastrointestinal Cancer, discusses immunotherapy in gastric cancer.
Latest:
Wireless DosimetryA new way to ensure your patients receive the proper radiation dose where they need it.
Latest:
Cancer Survivor Charlie Lustman Lives to Tell His StoryKeynote Presenter Cancer Survivor Charlie Lustman Lives to Tell His Story
Latest:
Dr. Kubicky on the Optimal Use of Radiation in Patients With Breast CancerCharlotte Kubicky, MD, PhD, associate professor of radiation medicine, School of Medicine, medical director, Tuality Oregon Health and Science Cancer Center, Oregon Health and Science University, discusses the optimal use of radiation in the treatment of patients with breast cancer.
Latest:
Primary Radiation Therapy for Myeloid Sarcoma of the Porta HepatisTreating myeloid sarcoma at the porta hepatis with 24 Gy over 12 fractions is a well-tolerated treatment that achieved a complete, durable response with minimal toxicity.
Latest:
Strategic Approaches to Biomarker Testing in NSCLC: Optimal TimingExperts reflect on the evolving landscape of biomarker testing in lung cancer, examining its crucial role in treatment decisions and advancements in perioperative and adjuvant therapies.
Latest:
Trilaciclib: Treatment ConsiderationsAdvantages associated with the administration of trilaciclib in appropriate patients receiving a chemotherapy-containing regimen for extensive-stage small cell lung cancer.
